Mariner LLC decreased its holdings in shares of Envista Holdings Co. (NYSE:NVST - Free Report) by 23.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 102,919 shares of the company's stock after selling 31,948 shares during the period. Mariner LLC owned about 0.06% of Envista worth $1,985,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently modified their holdings of the company. Sterling Capital Management LLC boosted its position in shares of Envista by 53.9% during the fourth quarter. Sterling Capital Management LLC now owns 11,105 shares of the company's stock worth $214,000 after buying an additional 3,888 shares during the period. Treasurer of the State of North Carolina boosted its position in shares of Envista by 0.6% during the 4th quarter. Treasurer of the State of North Carolina now owns 75,560 shares of the company's stock valued at $1,458,000 after purchasing an additional 480 shares in the last quarter. Bryce Point Capital LLC bought a new position in shares of Envista in the fourth quarter valued at $590,000. Massachusetts Financial Services Co. MA raised its position in shares of Envista by 9.5% during the fourth quarter. Massachusetts Financial Services Co. MA now owns 3,271,175 shares of the company's stock worth $63,101,000 after purchasing an additional 283,415 shares during the period. Finally, Trexquant Investment LP purchased a new stake in Envista during the fourth quarter valued at about $5,982,000.
Analyst Upgrades and Downgrades
NVST has been the topic of several recent analyst reports. Wells Fargo & Company set a $19.00 price target on Envista in a research report on Saturday, March 8th. Jefferies Financial Group raised their price target on Envista from $20.00 to $22.00 and gave the stock a "hold" rating in a research note on Thursday, January 23rd. UBS Group lowered their price target on Envista from $23.00 to $21.00 and set a "neutral" rating for the company in a research note on Monday, March 10th. New Street Research set a $19.00 price objective on shares of Envista in a research report on Thursday, March 6th. Finally, Needham & Company LLC restated a "hold" rating on shares of Envista in a research note on Thursday, March 6th. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and three have given a buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Hold" and a consensus target price of $19.96.
Check Out Our Latest Analysis on Envista
Envista Stock Performance
Envista stock traded down $0.02 during mid-day trading on Friday, reaching $15.96. The company had a trading volume of 2,273,467 shares, compared to its average volume of 2,506,221. The company has a 50 day moving average of $17.22 and a 200-day moving average of $19.11. The firm has a market cap of $2.75 billion, a price-to-earnings ratio of -2.46, a PEG ratio of 1.27 and a beta of 1.12. The company has a quick ratio of 1.76, a current ratio of 2.04 and a debt-to-equity ratio of 0.44. Envista Holdings Co. has a 52 week low of $14.22 and a 52 week high of $23.00.
Envista (NYSE:NVST - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.24 EPS for the quarter, topping analysts' consensus estimates of $0.23 by $0.01. Envista had a positive return on equity of 3.86% and a negative net margin of 44.56%. On average, sell-side analysts expect that Envista Holdings Co. will post 1 EPS for the current fiscal year.
Envista Company Profile
(
Free Report)
Envista Holdings Corporation, together with its subsidiaries, develops, manufactures, markets, and sells dental products in the United States, China, and internationally. The company operates in two segments, Specialty Products & Technologies, and Equipment & Consumables. The Specialty Products & Technologies segment offers dental implant systems, guided surgery systems, biomaterials, and prefabricated and custom-built prosthetics to oral surgeons, prosthodontists and periodontists, and general dentist; and brackets and wires, tubes and bands, archwires, clear aligners, digital orthodontic treatments, retainers, and other orthodontic laboratory products.
Featured Stories
Before you consider Envista, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Envista wasn't on the list.
While Envista currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
